Epilepsy is ubiquitous, but more devastating in the poorer regions of the world⋯ or is it?

Epilepsia

Volumn 55, Issue 9, 2014, Pages 1322-1325

  Wilmshurst, Jo M ^a   Birbeck, Gretchen L ^b   Newton, Charles R ^c,d,e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Africa; Epidemiology; Epilepsy; Incidence; Prevalence

Indexed keywords

ANTICONVULSIVE AGENT; PHENANTHRENE DERIVATIVE; STIGMALACTAM;

ANTICONVULSANT THERAPY; ARTICLE; EPILEPSY; HUMAN; INCIDENCE; MORTALITY; PREVALENCE; STIGMA; AFRICA; ECONOMICS; EPIDEMIOLOGY; HEALTH; HEALTH CARE DELIVERY; PSYCHOLOGICAL ASPECT;

AFRICA; EPIDEMIOLOGY; EPILEPSY; INCIDENCE; PREVALENCE;

ANTICONVULSANTS; DELIVERY OF HEALTH CARE; EPILEPSY; HUMANS; INCIDENCE; PHENANTHRENES; WORLD HEALTH;

EID: 84908024647     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12602     Document Type: Article

References (27)

1. Newton CR, Garcia HH. Epilepsy in poor regions of the world. Lancet 2012;380:1193-1201.
2. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-2223.
3. Preux PM, Druet-Cabanac M. Epidemiology and aetiology of epilepsy in sub-Saharan Africa. Lancet Neurol 2005;4 (Suppl. 1):21-31.
4. Ngugi AK, Bottomley C, Kleinschmidt I, et al. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 2010;51 (Suppl. 5):883-890.
5. Ngugi AK, Kariuki SM, Bottomley C, et al. Incidence of epilepsy: a systematic review and meta-analysis. Neurology 2011; 77 (Suppl. 10):1005-1012.
6. Burneo JG, Tellez-Zenteno J, Wiebe S. Understanding the burden of epilepsy in Latin America: a systematic review of its prevalence and incidence. Epilepsy Res 2005;66 (Suppl. 1-3):63-74.
7. Mac TL, Tran DS, Quet F, et al. Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review. Lancet Neurol 2007;6:533-543.
8. Diop AG, Hesdorffer DC, Logroscino G, et al. Epilepsy and mortality in Africa: a review of the literature. Epilepsia 2005;46 (Suppl. 11): 33-35.
9. Ngugi AK, Bottomley C, Kleinschmidt I, et al. Prevalence of active convulsive epilepsy in sub-Saharan Africa and associated risk factors: cross-sectional and case-control studies. Lancet Neurol 2013;12 (Suppl. 3):253-263.
10. Ngugi AK, Bottomley C, Fegan G, et al. Premature mortality in active convulsive epilepsy in rural Kenya: causes and associated factors. Neurology 2014;82 (Suppl. 7):582-589.
11. Ding D, Wang W, Wu J, et al. Premature mortality risk in people with convulsive epilepsy: long follow-up of a cohort in rural China. Epilepsia 2013;54 (Suppl. 3):512-517.
12. Mbewe E, Haworth A, Atadzhanov M, et al. Epilepsy-related knowledge, attitudes, and practices among Zambian police officers. Epilepsy Behav 2007;10 (Suppl. 3):456-462.
13. Baskind R, Birbeck GL. Epilepsy-associated stigma in sub-Saharan Africa: the social landscape of a disease. Epilepsy Behav 2005;7 (Suppl. 1):68-73.
14. Birbeck GL, Chomba E, Atadzhanov M, et al. Zambian teachers: what do they know about epilepsy and how can we work with them to decrease stigma? Epilepsy Behav 2006;9 (Suppl. 2):275-280.
15. Chomba E, Haworth A, Atadzhanov M, et al. Family environment and influence on children with epilepsy. Medical Journal of Zambia 2008;34 (Suppl. 3):116-119.
16. Birbeck G, Chomba E, Atadzhanov M, et al. The social and economic impact of epilepsy in Zambia: a cross-sectional study. Lancet Neurol 2007;6 (Suppl. 1):39-44.
17. Birbeck GL, Chomba EN, Atadzhanov M, et al. "If someone is bewitching you, better he should just kill you": Women's experiences living with epilepsy in Zambia. Am J Trop Med Hyg 2008;79 (Suppl. 2):168-172.
18. Carter JA, Molyneux CS, Mbuba CK, et al. The reasons for the epilepsy treatment gap in Kilifi, Kenya: using formative research to identify interventions to improve adherence to antiepileptic drugs. Epilepsy Behav 2012;25 (Suppl. 4):614-621.
19. Meyer AC, Dua T, Boscardin WJ, et al. Critical determinants of the epilepsy treatment gap: a cross-national analysis in resource-limited settings. Epilepsia 2012;53 (Suppl. 12):2178-2185.
20. Meyer AC, Dua T, Ma J, et al. Global disparities in the epilepsy treatment gap: a systematic review. Bull World Health Organ 2010;88 (Suppl. 4):260-266.
21. Mbuba CK, Ngugi AK, Newton CR, et al. The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies. Epilepsia 2008;49 (Suppl. 9): 1491-1503.
22. Mbuba CK, Ngugi AK, Fegan G, et al. Risk factors associated with the epilepsy treatment gap in Kilifi, Kenya: a cross-sectional study. Lancet Neurol 2012;11 (Suppl. 8):688-696.
23. Nolan SJ, Tudur Smith C, Pulman J, et al. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database Syst.Rev 2013;1:CD002217.
24. Ijff DM, Aldenkamp AP. Cognitive side-effects of antiepileptic drugs in children. Handb Clin Neurol 2013;111:707-718.
25. Pal DK, Das T, Chaudhury G, et al. Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet 1998;351:19-23.
26. Banu SH, Jahan M, Koli UK, et al. Side effects of phenobarbital and carbamazepine in childhood epilepsy: randomised controlled trial. BMJ 2007;9:1207.
27. Mbuba CK, Newton CR. Packages of care for epilepsy in low- and middle-income countries. PLoS Med 2009;6 (Suppl. 10):e1000162.